Tag: Neck

  • Nigeria first to rollout new Men5CV vaccine against meningitis

    Nigeria first to rollout new Men5CV vaccine against meningitis

    [ad_1]

    In a historic move, Nigeria has become the first country in the world to roll out a new vaccine (called Men5CV) recommended by the World Health Organization (WHO), which protects people against five strains of the meningococcus bacteria. The vaccine and emergency vaccination activities are funded by Gavi, the Vaccine Alliance, which funds the global meningitis vaccine stockpile, and supports lower-income countries with routine vaccination against meningitis. 

    Nigeria is one of the 26 meningitis hyper-endemic countries of Africa, situated in the area known as the African Meningitis Belt. Last year, there was a 50% jump in annual meningitis cases reported across Africa.

    In Nigeria, an outbreak of Neisseria meningitidis (meningococcus) serogroup C outbreak led to 1742 suspected meningitis cases, including 101 confirmed cases and 153 deaths in seven of 36 Nigerian states (Adamawa, Bauchi, Gombe, Jigawa, Katsina, Yobe, Zamfara) between 1 October 2023 and 11 March 2024. To quell the deadly outbreak, a vaccination campaign has been undertaken on 25–28 March 2024 to initially reach more than one million people aged 1-29 years.

    Meningitis is a serious infection that leads to the inflammation of the membranes (meninges) that surround and protect the brain and spinal cord. There are multiple causes of meningitis, including viral, bacterial, fungal and parasitic pathogens. Symptoms often include headache, fever and stiff neck. Bacterial meningitis is the most serious, can also result in septicaemia (blood poisoning), and can seriously disable or kill within 24 hours those that contract it.

    Meningitis is an old and deadly foe, but this new vaccine holds the potential to change the trajectory of the disease, preventing future outbreaks and saving many lives. Nigeria’s rollout brings us one step closer to our goal to eliminate meningitis by 2030.”


     Dr Tedros Adhanom Ghebreyesus, WHO Director-General

    The revolutionary new vaccine offers a powerful shield against the five major strains of the meningococcal bacteria (A, C, W, Y and X) in a single shot. All five strains cause meningitis and blood poisoning. This provides broader protection than the current vaccine used in much of Africa, which is only effective against the A strain.

    The new vaccine has the potential to significantly reduce meningitis cases and advance progress in defeating meningitis. This is especially important for countries like Nigeria where multiple serogroups are prevalent. The new vaccine uses the same technology as the meningitis A conjugate vaccine (MenAfriVac®), which wiped out meningococcal A epidemics in Nigeria.

    “Northern Nigeria, particularly the states of Jigawa, Bauchi and Yobe were badly hit by the deadly outbreak of meningitis, and this vaccine provides health workers with a new tool to both stop this outbreak but also put the country on a path to elimination,” said Prof. Muhammad Ali Pate of the Nigerian Ministry of Health and Social Welfare. “We’ve done a lot of work preparing health workers and the health system for the rollout of this new vaccine. We got an invaluable support from our populations despite this fasting period and from our community leaders especially the Emir of Gumel in Jigawa state who personally launched the vaccination campaign in the state. We’ll be monitoring progress closely and hopefully expanding the immunization in the coming months and years to accelerate progress.”

    This new multivalent conjugate vaccine was 13 years in the making and was based on a partnership between PATH and the Serum Institute of India. Financing from the UK government’s Foreign, Commonwealth and Development Office was critical to its development.

    In July 2023, WHO prequalified the new Men5CV vaccine (which has brand name MenFive®) and in October 2023 issued an official recommendation to countries to introduce the new vaccine. Gavi allocated resources for the Men5CV rollout in December 2023, which is currently available for outbreak response through the emergency stockpile managed by the International Coordinating Group (ICG) on Vaccine Provision, while roll-out through mass preventive campaigns is expected to start in 2025 across countries of the Meningitis Belt.

    “The rollout of one million vaccines in northern Nigeria will help save lives, prevent long-term illness and boost our goal of defeating meningitis globally by 2030,” said Andrew Mitchell, UK Minister for Development and Africa. “This is exactly the kind of scientific innovation, supported by the UK, which I hope is replicated in years to come to help us drive further breakthroughs, including wiping out other diseases.”

    WHO has been supporting the Nigeria Centre for Disease Control and Prevention (NCDC) in responding to the meningitis outbreak in the country. This includes disease surveillance, active case finding, sample testing, and case management. WHO and partners have also played a vital role in supporting Nigeria to prepare for the rollout of the new vaccine and training health workers.

    “Year after year, meningococcal meningitis has tormented countries across Africa,” said Dr Nanthalile Mugala, PATH’s Chief of Africa Region. “The introduction of MenFive® in Nigeria heralds a transformative era in the fight against meningococcal meningitis in Africa. Building on the legacy of previous vaccination efforts, this milestone reflects over a decade of unwavering, innovative partnerships. The promise of MenFive® lies not just in its immediate impact but in the countless lives it stands to protect in the years to come, moving us closer to a future free from the threat of this disease.”

    In 2019, WHO and partners launched theglobal roadmap to defeating meningitis by 2030. The roadmap sets a comprehensive vision towards a world free of meningitis, and has three goals:

    – elimination of bacterial meningitis epidemics;
    – reduction of cases of vaccine-preventable bacterial meningitis by 50% and deaths by 70%; and

    – reduction of disability and improvement of quality of life after meningitis due to any cause.

    “With outbreaks of infectious diseases on the rise worldwide, new innovations such as MenFive® are critical in helping us fight back,” said Aurélia Nguyen, Chief Programme Officer at Gavi, the Vaccine Alliance, which funds the global stockpile as well as vaccine rollout in lower-income countries. “This first shipment signals the start of Gavi support for a multivalent meningococcal conjugate vaccine (MMCV) program, which, with the required donor funding for our next five years of work, will see pentavalent meningococcal conjugate vaccines rolled out in high-risk countries. Thanks to vaccines, we have eliminated large and disruptive outbreaks of meningitis A in Africa: now we have a tool to respond to other serogroups that still cause large outbreaks resulting in long-term disability and deaths.” 

    Following Nigeria’s meningitis vaccine campaign, a major milestone on the road to defeat meningitis is the international summit on meningitis taking place in Paris in April 2024 where leaders will come together to celebrate progress, identify challenges and assess next steps. It is also an opportunity for country leaders and key partners to commit politically and financially to accelerate progress towards eliminating meningitis as a public health problem by 2030. 

    [ad_2]

    Source link

  • Tiktaalik fossil reveals key step in evolution of walking

    Tiktaalik fossil reveals key step in evolution of walking

    [ad_1]

    Before the evolution of legs from fins, the axial skeleton -; including the bones of the head, neck, back and ribs -; was already going through changes that would eventually help our ancestors support their bodies to walk on land. A research team including a Penn State biologist completed a new reconstruction of the skeleton of Tiktaalik, the 375-million-year-old fossil fish that is one of the closest relatives to limbed vertebrates. The new reconstruction shows that the fish’s ribs likely attached to its pelvis, an innovation thought to be crucial to supporting the body and for the eventual evolution of walking.

    A paper describing the new reconstruction, which used microcomputed tomography (micro-CT) to scan the fossil and reveal vertebrae and ribs of the fish that were previously hidden beneath rock, appeared April 2 in the journal Proceedings of the National Academy of Sciences.

    Tiktaalik was discovered in 2004, but key parts of its skeleton were unknown. These new high-resolution micro-CT scans show us the vertebrae and ribs of Tiktaalik and allow us to make a full reconstruction of its skeleton, which is vital to understanding how it moved through the world.”


    Tom Stewart, assistant professor of biology in the Eberly College of Science at Penn State and one of the leaders of the research team

    Unlike most fish, which have vertebrae and ribs that are the same along the length of the trunk, the axial skeletons of limbed vertebrates show dramatic differences in the vertebrae and ribs from the head region to the tail region. The evolution of this regionalization allowed the performance of specialized functions, one of which was a mechanical linkage between ribs in the sacral region to the pelvis that enabled support of the body by the hind limbs.

    The pelvic fins of fish are evolutionarily related to hind limbs in tetrapods -; four-limbed vertebrates, including humans. In fish, the pelvic fins and bones of the pelvic girdle are relatively small and float freely in the body. For the evolution of walking, the researchers explained, the hind limbs and pelvis became much larger and formed a connection to the vertebral column as a way of bracing the forces related to supporting the body.

    “Tiktaalik is remarkable because it gives us glimpses into this major evolutionary transition,” Stewart said. “Across its whole skeleton, we see a combination of traits that are typical of fish and life in water as well as traits that are seen in land-dwelling animals.”

    The original description of Tiktaalik focused on the front portion of the skeleton. Fossils were meticulously prepared to remove the surrounding matrix of rock and expose the skull, shoulder girdle and pectoral fins. The ribs in this area were large and expanded, suggesting that they may have supported the body in some way, but it was unclear exactly how they would have functioned. In 2014, the fish’s pelvis, discovered in the same location as the rest of the skeleton, was also cleaned of matrix and described.

    “From past studies, we knew that the pelvis was large, and we had a sense that the hind fins were large too, but until now couldn’t say if or how the pelvis interacted with the axial skeleton,” Stewart said. “This reconstruction shows, for the first-time, how it all fit together and gives us clues about how walking might have first evolved.”

    The researchers explained that, unlike our own hips where our bones fit tightly together, the connection between the pelvis and axial skeleton of Tiktaalik was likely a soft-tissue connection made of ligaments.

    “Tiktaalik had specialized ribs that would have connected to the pelvis by a ligament,” Stewart said. “It’s astonishing really. This creature has so many traits -; large pair of hind appendages, large pelvis, and connection between the pelvis and axial skeleton -; that were key to the origin of walking. And while Tiktaalik probably wasn’t walking across land, it was definitely doing something new. This was a fish that could likely prop itself up and push with its hind fin.”

    The new reconstruction of the skeleton also sheds light on specializations for head mobility in Tiktaalik and new details of the fish’s pelvic fin anatomy.

    “It’s incredible to see the skeleton of Tiktaalik captured in such vivid detail,” said Neil Shubin, Robert R. Bensley Distinguished Service Professor of Organismal Biology and Anatomy at the University of Chicago and one of the authors of the paper. “This study sets the stage for ones that explore how the animal moved about and interacted with its environment 375 million years ago.”

    In addition to Stewart and Shubin, the research team includes Justin B. Lemberg, Emily J. Hillan, and Isaac Magallanes at The University of Chicago, and Edward B. Daeschler at Academy of Natural Sciences of Drexel University.

    Support from the Brinson Foundation, the Biological Sciences Division of The University of Chicago, an anonymous donor to the Academy of Natural Sciences of Drexel University, and the U.S. National Science Foundation funded this research. Fieldwork was made possible by the Polar Continental Shelf Project of Natural Resources, Canada; the Department of Heritage and Culture, Nunavut; the hamlets of Resolute Bay and Grise Fiord of Nunavut; and the Iviq Hunters and Trappers of Grise Fiord.

    Source:

    Journal reference:

    Stewart, T. A., et al. (2024) The axial skeleton of Tiktaalik roseae. PNAS. doi.org/10.1073/pnas.2316106121.

    [ad_2]

    Source link

  • BMI influences efficacy of nerve-stimulation treatment for sleep apnea, study finds

    BMI influences efficacy of nerve-stimulation treatment for sleep apnea, study finds

    [ad_1]

    A nerve-stimulation treatment for obstructive sleep apnea that originally was approved only for people with body mass indexes (BMIs) in the healthy range recently was extended to patients with BMIs up to 40, a weight range generally described as severely obese. A healthy BMI ranges from 18.5 to 24.9.

    The expanded eligibility criteria for the treatment provide more sleep apnea patients with access to the increasingly popular therapy, known as hypoglossal nerve stimulation. However, new research from Washington University School of Medicine in St. Louis indicates that the likelihood of successful nerve-stimulation treatment drops significantly as a patient’s weight rises above a healthy range.

    The study, which appears April 4 in JAMA Otolaryngology-Head & Neck Surgery, is based on a retrospective analysis of treatment success in 76 sleep apnea patients with BMIs of less than 35.

    Our study shows that the more overweight you are, the less likely it is that nerve-stimulation treatment will be effective in treating your sleep apnea.” 

    Eric C. Landsness, MD, PhD, senior author, assistant professor of neurology

    “I’m not saying that we shouldn’t put this device in patients with a BMI of 38 or 40. But my job as a physician is to help overweight patients make an informed decision, to better understand their odds of success and realize that the chances of it working for them may be a lot less.”

    Obstructive sleep apnea is caused by relaxation of muscles in the mouth and throat when a person is asleep. Muscle slumping can cause a partial or complete blockage of airflow and oxygen supply, especially in people with large tongues, thick necks and narrow airways. Blockages may cause people with sleep apnea to stop breathing for seconds (sometimes more than a minute), until they startle themselves awake and gasp for breath, a cycle that often repeats through the night. Untreated sleep apnea can cause serious health problems, including excessive daytime sleepiness, headaches, strokes, irregular heart rhythms and other cardiovascular issues.

    Sleep apnea most often is treated with a bedside continuous positive airway pressure (CPAP) machine, which maintains open airways via a breathing hose and tightly fitting face mask. CPAP machines are effective, but they can be loud and uncomfortable and are largely unpopular. About half of those who try the approach fail to stick with it.

    To many patients, hypoglossal nerve stimulation looks like an appealing alternative to CPAP machines. The therapy is driven by a small, battery-operated device implanted just above the ribs. A small wire is run internally up the chest and into the jaw, where it connects to the hypoglossal, a nerve that controls tongue muscles responsible for keeping the upper airway open during sleep.

    Each time the patient takes a breath, the device delivers electrical impulses to the hypoglossal nerve, causing the tongue to move forward just far enough to avoid the airway blockages that drive sleep apnea.

    The first hypoglossal nerve-stimulation device (brand name Inspire) was approved by the U.S. Food and Drug Administration (FDA) in 2014 for use in patients with BMIs less than 25 whose moderate to severe sleep apnea has failed treatment with other, more established therapies. Since then, eligibility requirements have loosened, with the FDA now allowing the device to be used in patients with BMIs as high as 40 and Medicare providing coverage for patients with BMIs up to 35.

    Landsness, a sleep researcher who treats patients with sleep apnea, was surprised by the changes in the eligibility criteria. To understand how the device performs in people of varying sizes, he and colleagues performed an independent evaluation using data from 78 people with BMIs up to 35 who received implants of the nerve-stimulation device at the Washington University Sleep Medicine Center from 2019 through 2023.

    The primary study finding was that, overall, the device works. Three out of four patients showed significant improvement in apnea symptoms in the year following implantation. Most study participants experienced symptom reductions of at least 50%, with many showing dramatic reductions to near normal or mild levels of sleep apnea.

    However, among overweight study participants with BMIs of 32 to 35, the results were less positive, with the likelihood of successful treatment estimated to be 75% lower than those of study participants with lower BMIs.

    “Body mass index is clearly an important factor in predicting whether hypoglossal nerve stimulation will work for an individual patient,” Landsness said. “Our study shows an almost linear relationship between BMI and treatment success. For every unit of BMI increase over 32, the odds of successful treatment decrease by about 17%.”

    Inspire is the only FDA-approved hypoglossal nerve-stimulation device available in the United States. The company also markets the device in Europe, Japan and other countries. About 50,000 patients worldwide have been implanted with it.

    Implantation of a hypoglossal nerve-stimulation device is a relatively simple outpatient surgery. Among the biggest concerns for patients are in terms of money and time. Landsness estimates that the therapy can cost from $50,000 to $100,000 out of pocket without insurance and take a year to be fully optimized.

    “We have patients coming to us who really want this treatment, because they view it as a life-changing alternative to CPAP,” Landsness said. “It certainly can work for some people, but we don’t want to recommend it to patients if there’s a chance their BMIs will affect the device’s usefulness.”

    Source:

    Journal reference:

    Patel, R. M., et al. (2024). Response to Hypoglossal Nerve Stimulation Changes With Body Mass Index and Supine Sleep. JAMA Otolaryngology–Head & Neck Surgery. doi.org/10.1001/jamaoto.2024.0261.

    [ad_2]

    Source link

  • Chronic pain, metal jaws, and futile treatments

    Chronic pain, metal jaws, and futile treatments

    [ad_1]

    A TMJ patient in Maine had six surgeries to replace part or all of the joints of her jaw.

    Another woman in California, desperate for relief, used a screwdriver to lengthen her jawbone daily, turning screws that protruded from her neck.

    A third in New York had bone from her rib and fat from her belly grafted into her jaw joint, and twice a prosthetic eyeball was surgically inserted into the joint as a placeholder in the months it took to make metal hinges to implant into her jaw.

    “I feel like Mr. Potato Head,” said Jenny Feldman, 50, of New York City, whose medical records show she’s had at least 24 TMJ-related surgeries since she was a teenager. “They’re moving ribs into my face, and eyeballs, and I feel like a toy … put together [by] somebody just tinkering around.”

    These are some of the horrors of temporomandibular joint disorders, known as TMJ or TMD, which afflict up to 33 million Americans, according to the National Institutes of Health. Dentists have attempted to heal TMJ patients for close to a century, and yet the disorders remain misunderstood, under-researched, and ineffectively treated, according to an investigation by KFF Health News and CBS News.

    Dental care for TMJ can do patients more harm than good, and a few fall into a spiral of futile surgeries that may culminate in their jaw joints being replaced with metal hinges, according to medical and dental experts, patients, and their advocates speaking in interviews and video testimony submitted to the FDA.

    TMJ disorders cause pain and stiffness in the jaw and face that can range from discomfort to disabling, with severe symptoms far more common in women. Dentists have commonly treated the disorder with splints and orthodontics. And yet these treatments are based on “strongly held beliefs” and “inadequate research” — not compelling scientific evidence nor consistent results — according to the National Academies of Sciences, Engineering and Medicine, which reviewed decades of research on the topic. The NIH echoes this message, warning that there is “not a lot of evidence” that splints reduce pain and recommends “staying away” from any treatment that permanently changes the teeth, bite, or jaw.

    “I would say that the treatments overall have not been effective, and I can understand why,” said Rena D’Souza, director of the NIH’s National Institute of Dental and Craniofacial Research. “We don’t understand the disease.”

    For this investigation, journalists with KFF Health News and CBS News interviewed 10 TMJ patients with severe symptoms who said they felt trapped by an escalating series of treatments that began with splints or dental work and grew into multiple surgeries with diminishing returns and dwindling hope.

    In every interview, the patients said the TMJ pain worsened throughout their treatment and they regretted some, if not all, of the care they received.

    “The grand irony to me is that I went to the doctor for headaches and neck pain, and I’ve had 13 surgeries on my face and jaw, and I still have even worse neck pain,” said Tricia Kalinowski, 63, of Old Orchard Beach, Maine. “And I live with headaches and jaw pain every day.”

    TMJ has become an umbrella term for about 30 disorders that afflict roughly 5% to 10% of Americans. Minor symptoms may not require treatment at all, and many cases resolve by themselves over time. Severe symptoms include chronic pain and may limit the ability to eat, sleep, or talk.

    In a comprehensive study of TMJ disorders by the national academies, including input from more than 110 patients, experts found that most health care professionals, including dentists, have received “minimal or no training” on TMJ disorders and patients are “often harmed” by “overly aggressive” care and the lack of proven treatments.

    Almost 100 years this has been in dentistry, and look at what we have… A whole ton of people pretending they know everything, and we don’t know anything.”


    Terrie Cowley, TMJ patient

    The American Dental Association, which represents about 160,000 dentists nationwide and establishes guidelines for the profession, declined an interview request. In a written statement, ADA President Linda Edgar said that TMJ disorders are “often managed rather than cured” and that it sees “great potential” in new efforts to research more treatment options.

    Terrie Cowley, a longtime TMJ patient who leads the TMJ Association, an advocacy group that has spoken with tens of thousands of patients, said she was so disillusioned with dental care for TMJ that she advises many patients to avoid treatment entirely, potentially for years.

    “Almost 100 years this has been in dentistry, and look at what we have,” Cowley said. “A whole ton of people pretending they know everything, and we don’t know anything.”

    ‘Not taken seriously’

    Scientific studies have found that TMJ disorders arise up to nine times as often in women, particularly those in their 20s and 30s, leading to theories that the cause may be linked to reproductive hormones. But a true understanding of TMJ disorders remains elusive.

    Kyriacos Athanasiou, a biomedical engineering professor at the University of California-Irvine, said it was because TMJ disorders are more prevalent among women that they were historically dismissed as neither serious nor complex, slowing research into the cause and treatment.

    The resulting dearth of knowledge, which is glaring when compared with other joints, has been “a huge disservice” to patients, Athanasiou said. In a 2021 study he co-authored, researchers found that the knee, despite being a much simpler joint, was the subject of about six times as many research papers and grants in a single year than the jaw joint.

    D’Souza agreed that TMJ disorders were “not taken seriously” for decades, along with other conditions that predominantly affect women.

    “That has been a bias that is really long-standing,” she said. “And it’s certainly affected the progress of research.”

    Patients have felt the effect too. In interviews, female patients said they felt patronized or trivialized by male health care providers at some point in their TMJ treatment, if not throughout. Some said they felt blamed for their own pain because they were viewed as too stressed and clenching their jaw too much.

    “We desperately need research to find the reasons why more women get TMJ disease,” wrote Lisa Schmidt, a TMJ Association board member, in a 2021 newsletter from the organization. “And surgeons need to stop blaming this condition on women.”

    Every time you have a surgery, your pain gets worse… If I could go back in time and go talk to younger Lisa, I would say ‘Run!’”


    Lisa Schmidt, TMJ patient

    Schmidt, 52, of Poway, California, said she was diagnosed with TMJ disorder in 2000 due to headaches, and an orthodontist immediately recommended her for a splint, braces, and surgery.

    After wearing the splint for only three days, Schmidt said, she was in “excruciating pain” and could no longer open her mouth far enough to eat solid food. Schmidt said she spent the next 17 years stuck on a “surgery carousel” with no escape, and eventually was in so much pain she abandoned her career as an aerospace scientist who worked alongside NASA astronauts.

    Schmidt said her low point came in 2016. In an attempt to restore bone that had been cut away in prior surgeries, a surgeon implanted long screws into Schmidt’s jaw that protruded downward out of her neck. Schmidt said she was instructed to tighten those screws with a screwdriver daily for about 20 days, lengthening the corners of her jaw to restore the bone that had been lost. It didn’t work, Schmidt said, and she was left in more pain than ever.

    “Every time you have a surgery, your pain gets worse,” Schmidt said. “If I could go back in time and go talk to younger Lisa, I would say ‘Run!’”

    Lack of sufficient evidence

    Many of the shortcomings of TMJ care were laid bare in the 426-page report published by the national academies in March 2020 that received limited public attention amid the coronavirus pandemic. The report’s 18 authors include medical and dental experts from Harvard, Duke, Clemson, Michigan State, and Johns Hopkins universities.

    Sean Mackey, a Stanford professor who co-led the team, said it found that patients were often steered toward costly treatments and “pathways of futility” instead of being taught to manage their pain through strategies and therapies with “good evidence.”

    “We learned it’s a quagmire,” Mackey said. “There is a perverse incentive in our society that pays more for things we do to people than [for] talking and listening to people. … Some of those procedures, some of those surgeries, clearly are not helping people.”

    Among its many findings, the national academies said it has been widely assumed in the field of dentistry that TMJ disorders are caused by a misaligned bite, so treatments have focused on patients’ teeth and bite for more than 50 years. But there is a “notable absence of sufficient evidence” that a misaligned bite is a cause of TMJ disorders, and the belief traces back to “inadequate research” in the 1960s that has been repeated in “poorly-designed studies” ever since, the report states.

    Therefore, TMJ treatment that makes permanent changes to the bite — like installing braces or crowns or grinding teeth down — has “no supporting evidence,” according to the national academies report. The NIH warns that these TMJ treatments “don’t work and may make the problem worse.”

    Dental splints, the most common TMJ treatment, also known as night guards or mouth guards, are removable dental appliances that are molded to fit over the teeth and can cost hundreds or even thousands of dollars out-of-pocket, according to the TMJ Association. Like most medical devices, splints generally go through the FDA’s 510(k) clearance process, which does not require each splint to be proven effective before it can be sold, according to the agency.

    The national academies’ report states that splints produce “mixed results” for TMJ patients, and even when splints succeed at reducing jaw pain it is not understood why they work. Hundreds of splint designs exist, the report states, and some dentists reject research that challenges the use of splints unless it focuses on the specific design they prefer.

    “Because of the hundreds of variations in [splint] design, it is unlikely that any study could ever be conducted that will be considered sufficient to a particular dentist with a pre-existing belief about the effectiveness of one appliance,” the report states.

    Other treatments fare no better. The FDA has not labeled any drugs specifically for TMJ disorders, and pain medicines can be too weak or addictive to be a long-term solution, according to the TMJ Association. Botox injections may ease pain but have raised concerns about bone loss during animal testing. The NIH warns that minor surgeries that flush the jaw with liquid bring only temporary pain relief and that more complex surgeries should be reserved for severe cases because they have yet to be proved safe or effective in the long term.

    To improve care, the national academies called for better education about TMJ disorders across medicine and dentistry and more research funding from the NIH, which has a “ripple effect” on research and training across the nation.

    Since the 2020 report, the NIH has launched a TMJ research collaborative and increased annual research funding from about $15 million to about $34 million, D’Souza said. TMJ care was added to the standards that dental schools must teach to be accredited in 2022. The national academies launched an ongoing forum on TMJ disorders last year.

    But TMJ funding still pales in comparison to other ailments. The NIH spends billions each year to research deadly diseases, like cancer and heart disease, that also afflict large numbers of Americans. It spends millions more on research of non-life-threatening conditions like arthritis, back pain, eczema, and headaches.

    Mackey noted that much of the NIH’s spending is allocated by Congress.

    “If Congress comes in and says, ‘We want to devote X amount of money to [TMJ],’ all of the sudden you will see an increase in money,” Mackey said. “So that’s my message to people out there: Raise your voices. Write your legislator.”

    Total jaw replacements

    Plagued by TMJ symptoms, and after failed treatments, some patients turn to a last resort: replacing their jaw joint with synthetic implants. Surgeons might replace the cartilage disk at the core of the joint or use “total joint replacement surgery” to fasten a metal hinge to the bones of the skull.

    But the implants have a harrowing history: Several disk implants were recalled or discontinued in the ’90s due to dangerous failures. The FDA now classifies TMJ implants among its most closely monitored medical devices because the products on the market today can cause “adverse health consequences” if the devices fail, according to the agency’s website.

    Two companies, Zimmer Biomet and Stryker, make the only total jaw replacement implants currently sold in the U.S.

    Zimmer Biomet, which has made its implant for more than two decades, described it in email statements as “a safe and efficacious solution” for patients who need their jaw joint replaced, either due to TMJ disorders, failed surgeries, injuries, or other ailments. An FDA-mandated study completed in 2017 found about 14% of patients who get the Zimmer Biomet implant require additional surgery or removal within 10 years, said agency spokesperson Carly Pflaum.

    Stryker, which in 2021 bought a company that made a total jaw replacement implant and now makes the implant itself, declined to comment. Although the NIH has advised TMJ patients to avoid surgery since at least 2022, Stryker launched a “patient-facing website” for the implant last year and is recruiting surgeons to be added to a “surgeon locator” feature on the site, according to posts on Facebook and LinkedIn.

    A study of the Stryker implant’s success rate was mandated by the FDA and completed in 2020, but the agency has yet to make the results public.

    D’Souza, the NIH official, said that based on her professional experience, she estimates that most total jaw replacement surgeries are ultimately ineffective.

    “The success rate is low,” D’Souza said. “It is not very encouraging.”

    Multiple patients provided KFF Health News and CBS News with medical records showing their total jaw replacement implants had to be removed due to malfunction, infection, or previously unknown metal allergies. Several patients said that since their implants were removed months or years ago, they have lived with no hinge in their jaw at all.

    Kalinowski, the TMJ patient in Maine, has had portions of her jaw joint replaced six times, including receiving four implants. Her medical records show that the cartilage disk on her right side was replaced in 1986 with an implant that was later recalled and again in 1987 with another that was later discontinued. Her left and right disks were replaced in 1992 with a muscle flap and rib graft, respectively, and her entire right joint was replaced with yet another implant that was later discontinued in 1998. Both joints were replaced again in 2015, her records show.

    Since then, Kalinowski said, her artificial jaw has functioned properly, although she remains in pain and cannot move her jaw from side to side. Her mouth hangs open when her face is at rest, and she drinks protein shakes for lunch because it’s easier than struggling with solid food.

    But the “worst part,” Kalinowski said, is that her surgeries caused nerve damage on her lower face, and so she has not felt her husband’s kisses since the ’90s.

    “If there was one moment in my life I could take back and do over again, it would be that first surgery. Because it set me on a trajectory,” Kalinowski said. “And it never goes away.”

    CBS News producer Nicole Keller contributed to this article.




    Kaiser Health NewsThis article was reprinted from khn.org, a national newsroom that produces in-depth journalism about health issues and is one of the core operating programs at KFF – the independent source for health policy research, polling, and journalism.

    [ad_2]

    Source link

  • Stem cell therapy safe and potentially beneficial for spinal cord injury patients

    Stem cell therapy safe and potentially beneficial for spinal cord injury patients

    [ad_1]

    A Mayo Clinic study shows stem cells derived from patients’ own fat are safe and may improve sensation and movement after traumatic spinal cord injuries. The findings from the phase 1 clinical trial appear in Nature Communications. The results of this early research offer insights on the potential of cell therapy for people living with spinal cord injuries and paralysis for whom options to improve function are extremely limited.

    In the study of 10 adults, the research team noted seven participants demonstrated improvements based on the American Spinal Injury Association (ASIA) Impairment Scale. Improvements included increased sensation when tested with pinprick and light touch, increased strength in muscle motor groups, and recovery of voluntary anal contraction, which aids in bowel function. The scale has five levels, ranging from complete loss of function to normal function. The seven participants who improved each moved up at least one level on the ASIA scale. Three patients in the study had no response, meaning they did not improve but did not get worse.

    This study documents the safety and potential benefit of stem cells and regenerative medicine. Spinal cord injury is a complex condition. Future research may show whether stem cells in combination with other therapies could be part of a new paradigm of treatment to improve outcomes for patients.”


    Mohamad Bydon, M.D., a Mayo Clinic neurosurgeon and first author of the study

    No serious adverse events were reported after stem cell treatment. The most commonly reported side effects were headache and musculoskeletal pain that resolved with over-the-counter treatment.

    In addition to evaluating safety, this phase 1 clinical trial had a secondary outcome of assessing changes in motor and sensory function. The authors note that motor and sensory results are to be interpreted with caution given limits of phase 1 trials. Additional research is underway among a larger group of participants to further assess risks and benefits.

    The full data on the 10 patients follows a 2019 case report that highlighted the experience of the first study participant who demonstrated significant improvement in motor and sensory function.

    Stem cells’ mechanism of action not fully understood

    In the multidisciplinary clinical trial, participants had spinal cord injuries from motor vehicle accidents, falls and other causes. Six had neck injuries; four had back injuries. Participants ranged in age from 18 to 65.

    Participants’ stem cells were collected by taking a small amount of fat from a 1- to 2-inch incision in the abdomen or thigh. Over four weeks, the cells were expanded in the laboratory to 100 million cells and then injected into the patients’ lumbar spine in the lower back. Over two years, each study participant was evaluated at Mayo Clinic 10 times.

    Although it is understood that stem cells move toward areas of inflammation -; in this case the location of the spinal cord injury -; the cells’ mechanism of interacting with the spinal cord is not fully understood, Dr. Bydon says. As part of the study, researchers analyzed changes in participants’ MRIs and cerebrospinal fluid as well as in responses to pain, pressure and other sensation. The investigators are looking for clues to identify injury processes at a cellular level and avenues for potential regeneration and healing.

    The spinal cord has limited ability to repair its cells or make new ones. Patients typically experience most of their recovery in the first six to 12 months after injuries occur. Improvement generally stops 12 to 24 months after injury. One unexpected outcome of the trial was that two patients with cervical spine injuries of the neck received stem cells 22 months after their injuries and improved one level on the ASIA scale after treatment.

    Two of three patients with complete injuries of the thoracic spine -; meaning they had no feeling or movement below their injury between the base of the neck and mid-back -; moved up two ASIA levels after treatment. Each regained some sensation and some control of movement below the level of injury. Based on researchers’ understanding of traumatic thoracic spinal cord injury, only 5% of people with a complete injury would be expected to regain any feeling or movement.

    “In spinal cord injury, even a mild improvement can make a significant difference in that patient’s quality of life,” Dr. Bydon says.

    Research continues into stem cells for spinal cord injuries

    Stem cells are used mainly in research in the U.S., and fat-derived stem cell treatment for spinal cord injury is considered experimental by the Food and Drug Administration.

    Between 250,000 and 500,000 people worldwide suffer a spinal cord injury each year, according to the World Health Organization.

    An important next step is assessing the effectiveness of stem cell therapies and subsets of patients who would most benefit, Dr. Bydon says. Research is continuing with a larger, controlled trial that randomly assigns patients to receive either the stem cell treatment or a placebo without stem cells.

    “For years, treatment of spinal cord injury has been limited to supportive care, more specifically stabilization surgery and physical therapy,” Dr. Bydon says. “Many historical textbooks state that this condition does not improve. In recent years, we have seen findings from the medical and scientific community that challenge prior assumptions. This research is a step forward toward the ultimate goal of improving treatments for patients.”

    Dr. Bydon is the Charles B. and Ann L. Johnson Professor of Neurosurgery. This research was made possible with support from Leonard A. Lauder, C and A Johnson Family Foundation, The Park Foundation, Sanger Family Foundation, Eileen R.B. and Steve D. Scheel, Schultz Family Foundation, and other generous Mayo Clinic benefactors. The research is funded in part by a Mayo Clinic Transform the Practice grant.

    Source:

    Journal reference:

    Bydon, M., et al. (2024). Intrathecal delivery of adipose-derived mesenchymal stem cells in traumatic spinal cord injury: Phase I trial. Nature Communications. doi.org/10.1038/s41467-024-46259-y.

    [ad_2]

    Source link

  • Ultrasound technology shows promise in detecting thoracic surface vibrations

    Ultrasound technology shows promise in detecting thoracic surface vibrations

    [ad_1]

    The thorax, the part of the body between the neck and abdomen, provides medical professionals with a valuable window into a patient’s respiratory health. By evaluating sound vibrations produced by the airflow induced within the lungs and bronchial tree during normal breathing as well as those produced by the larynx during vocalizations, doctors can identify potential disease-related abnormalities within the respiratory system.

    But, among other shortcomings, common respiratory assessments can be subjective and are only as good as the quality of the exam. While the advent of multipoint electronic stethoscopes has helped in terms of identifying abnormalities during normal breathing, there remains a dearth of technological devices that can help characterize surface vibrations produced by vocalizations.

    In AIP Advances, by AIP Publishing, a team of French researchers demonstrated the efficacy of ultrasound technology to detect low-amplitude movements produced by vocalizations at the surface of the chest. They also demonstrated the possibility of using the “airborne ultrasound surface motion camera” (AUSMC) to map these vibrations during short durations so as to illustrate their evolution.

    AUSMC is a new imaging technology that allows the observation of the human thorax surface vibrations due to respiratory and cardiac activities at high frame rates of typically 1,000 images per second. The technology shares the physical principle of conventional ultrasound Doppler imaging, but it does not require a probe to be applied on the skin.”


    Mathieu Couade, Author

    The researchers tested the AUSMC on 77 healthy volunteers to image the surface vibrations caused by natural vocalizations with the aim of reproducing the “vocal fremitus” – vocalization-induced vibrations on the surface of the body – as typically analyzed during physical examination of the thorax. Surface vibrations induced were detectable on all subjects, they reported.

    “The spatial distribution of vibrational energy was found to be asymmetric to the benefit of the right size of the chest, and frequency dependent in the anteroposterior axis,” said Couade. “As expected, the frequency distribution of vocalization does not overlap between men and women, with the latter being higher.”

    Ongoing clinical trials will use the AUSMC to focus on the identification of lung pathologies. But the researchers are hopeful that the technology, coupled with artificial intelligence algorithms, could usher in a new era of thorax examination in which vibration patterns can be isolated. This would offer a much better window on respiratory health and enable better diagnoses of respiratory diseases.

    Source:

    Journal reference:

    Wintzenrieth, F., et al. (2024) Airborne ultrasound for the contactless mapping of surface thoracic vibrations during human vocalizations: A pilot study. AIP Advances. doi.org/10.1063/5.0187945.

    [ad_2]

    Source link

  • Soft, stretchy throat patch empowers speech in people with voice disorders

    Soft, stretchy throat patch empowers speech in people with voice disorders

    [ad_1]

    People with voice disorders, including those with pathological vocal cord conditions or who are recovering from laryngeal cancer surgeries, can often find it difficult or impossible to speak. That may soon change.

    A team of UCLA engineers has invented a soft, thin, stretchy device measuring just over 1 square inch that can be attached to the skin outside the throat to help people with dysfunctional vocal cords regain their voice function. Their advance is detailed this week in the journal Nature Communications.

    The new bioelectric system, developed by Jun Chen, an assistant professor of bioengineering at the UCLA Samueli School of Engineering, and his colleagues, is able to detect movement in a person’s larynx muscles and translate those signals into audible speech with the assistance of machine-learning technology -; with nearly 95% accuracy.

    The breakthrough is the latest in Chen’s efforts to help those with disabilities. His team previously developed a wearable glove capable of translating American Sign Language into English speech in real time to help users of ASL communicate with those who don’t know how to sign.

    The tiny new patch-like device is made up of two components. One, a self-powered sensing component, detects and converts signals generated by muscle movements into high-fidelity, analyzable electrical signals; these electrical signals are then translated into speech signals using a machine-learning algorithm. The other, an actuation component, turns those speech signals into the desired voice expression.

    The two components each contain two layers: a layer of biocompatible silicone compound polydimethylsiloxane, or PDMS, with elastic properties, and a magnetic induction layer made of copper induction coils. Sandwiched between the two components is a fifth layer containing PDMS mixed with micromagnets, which generates a magnetic field.

    Utilizing a soft magnetoelastic sensing mechanism developed by Chen’s team in 2021, the device is capable of detecting changes in the magnetic field when it is altered as a result of mechanical forces -; in this case, the movement of laryngeal muscles. The embedded serpentine induction coils in the magnetoelastic layers help generate high-fidelity electrical signals for sensing purposes.

    Measuring 1.2 inches on each side, the device weighs about 7 grams and is just 0.06 inch thick. With double-sided biocompatible tape, it can easily adhere to an individual’s throat near the location of the vocal cords and can be reused by reapplying tape as needed.

    Voice disorders are prevalent across all ages and demographic groups; research has shown that nearly 30% of people will experience at least one such disorder in their lifetime. Yet with therapeutic approaches, such as surgical interventions and voice therapy, voice recovery can stretch from three months to a year, with some invasive techniques requiring a significant period of mandatory postoperative voice rest.

    Existing solutions such as handheld electro-larynx devices and tracheoesophageal- puncture procedures can be inconvenient, invasive or uncomfortable,” said Chen who leads the Wearable Bioelectronics Research Group at UCLA, and has been named one the world’s most highly cited researchers five years in a row. “This new device presents a wearable, non-invasive option capable of assisting patients in communicating during the period before treatment and during the post-treatment recovery period for voice disorders.”

    How machine learning enables the wearable tech

    In their experiments, the researchers tested the wearable technology on eight healthy adults. They collected data on laryngeal muscle movement and used a machine-learning algorithm to correlate the resulting signals to certain words. They then selected a corresponding output voice signal through the device’s actuation component.

    The research team demonstrated the system’s accuracy by having the participants pronounce five sentences -; both aloud and voicelessly -; including “Hi, Rachel, how are you doing today?” and “I love you!”

    The overall prediction accuracy of the model was 94.68%, with the participants’ voice signal amplified by the actuation component, demonstrating that the sensing mechanism recognized their laryngeal movement signal and matched the corresponding sentence the participants wished to say.

    Going forward, the research team plans to continue enlarging the vocabulary of the device through machine learning and to test it in people with speech disorders.

    Other authors of the paper are UCLA Samueli graduate students Ziyuan Che, Chrystal Duan, Xiao Wan, Jing Xu and Tianqi Zheng -; all members of Chen’s lab.

    The research was funded by the National Institutes of Health, the U.S. Office of Naval Research, the American Heart Association, Brain & Behavior Research Foundation, the UCLA Clinical and Translational Science Institute, and the UCLA Samueli School of Engineering.

    Source:

    Journal reference:

    Che, Z., et al. (2024). Speaking without vocal folds using a machine-learning-assisted wearable sensing-actuation system. Nature Communications. doi.org/10.1038/s41467-024-45915-7.

    [ad_2]

    Source link

  • UCLA researchers uncover dual role of GAN gene in neurological disorder, head and neck cancer

    UCLA researchers uncover dual role of GAN gene in neurological disorder, head and neck cancer

    [ad_1]

    Findings

    Researchers from the UCLA Health Jonsson Comprehensive Cancer Center show for the first time that a gene usually linked to giant axonal neuropathy, a rare and severe neurological condition, also plays a role in inhibiting aggressive tumor cell growth in head and neck cancers.

    The team found when the specific genetic variant (GAN gene exon 8 SNP T allele) of the GAN gene isn’t present, it leads to the production of certain proteins that make cancer cells more likely to spread and become resistant to treatment.

    These findings suggest that the presence of the genetic variant and higher expression of the GAN gene product gigaxonin may contribute to better survival in head and neck cancers and could potentially be used as diagnostic markers for identifying less aggressive forms of the disease.

    Background

    There are multiple neurodegenerative diseases that are associated with an increase risk of cancer. This increased risk is often associated with gene mutations that hinder the cell’s ability to repair DNA damage properly. Giant axonal neuropathy, a rare genetic disorder that leads to progressive damage to the peripheral nerves and central nervous system, is caused by mutations in the GAN gene, resulting in loss of expression of the protein called gigaxonin. This protein is crucial for maintaining the structural integrity of cells. In previous studies related to head and neck cancer, the UCLA team found that gigaxonin interacts with another protein called p16 to add a molecule called ubiquitin to a protein called NF-κB. This process, known as ubiquitination, is a way cells regulate the activity of proteins. However, the exact role of gigaxonin in cancer has not yet been well understood. Here, authors show that ubiquitination of NF-κB results in downregulation of Snail, a protein associated with epithelial to mesenchymal transition (EMT), also known as metastasis. Thus, expression of gigaxonin suppresses aggressive growth of human cancer cells.

    Method

    To gain insight into the role of gigaxonin in tumor development, investigators analyzed normal and tumor DNA from cervical and head and neck cancers. They also examined cancer cell lines with different genetic variations to understand the relationship between the genetic variation, gigaxonin expression, and the growth of cancer cells, including their response to cisplatin, a type of chemotherapy. Additionally, they investigated how gigaxonin is involved in ubiquitinating a transcription factor NF-κB and possibly associated with the development of head and neck cancer.

    Impact

    The study provides insights into the molecular mechanisms underlying head and neck cancer progression. If validated in additional studies, the use of gigaxonin as a diagnostic marker could help lead to the development of targeted therapies based on the gigaxonin pathway.

    Journal

    The study was published in Cancer Research Communications, a journal of the American Association for Cancer Research.

    Authors

    The co-senior authors are Eri Srivatsan, a professor of surgery at the Veterans Affairs Greater Los Angeles Healthcare System (VA GLAHS) Medical Center and the David Geffen School of Medicine at UCLA, and Dr. Daniel Shin, an assistant professor of medicine at the VA GLAHS Medical Center, and David Geffen School of Medicine. Both are members of the UCLA Health Jonsson Comprehensive Cancer Center and Molecular Biology Institute. The study’s first author is Mysore Veena, a scientist at the Geffen School of Medicine. Other UCLA authors include Jungmo Gahng, Dr. Mustafa Alani, Albert Ko, Saroj Basak, Isabelle Liu, Kimberly Hwang, Jenna Chatoff, Natarajan Venkatesan, Marco Morselli, Weihong Yan, Ibraheem Ali, Karolina Elżbieta Kaczor-Urbanowicz, Bhavani Shankara Gowda, Patrick Frost, Matteo Pellegrini, Dr. Neda Moatamed and Dr. Marilene Wang.

    Funding

    This work was supported in part by the VA GLAHS, West Los Angeles Surgical Education Research Program, and the Conquer Cancer Foundation/American Society of Clinical Oncology.

    [ad_2]

    Source link

  • Chewing tobacco linked to higher stroke and cancer risk, study finds

    Chewing tobacco linked to higher stroke and cancer risk, study finds

    [ad_1]

    In a recent study in the journal Nature Communications, researchers systematically reviewed and synthesized the literature on the health risks associated with chewing tobacco. Their results indicate that people who chew tobacco are significantly more likely to suffer from strokes and several cancers.

    While chewing tobacco is not as prevalent as smoking cigarettes, estimates suggest that more than 270 million people use smokeless tobacco products, of whom the majority live in India and Bangladesh. Smoking has declined since the 1990s, while the popularity of chewing tobacco appears to have increased, including among women.

    The health risks of chewing tobacco are less understood compared to the almost universal consensus on the harms caused by cigarettes and other forms of smoking. However, smokeless tobacco is thought to be a carcinogen.

    Study: Health effects associated with chewing tobacco: a Burden of Proof study. Image Credit: bildfokus.se / ShutterstockStudy: Health effects associated with chewing tobacco: a Burden of Proof study. Image Credit: bildfokus.se / Shutterstock

    About the study

    In this study, researchers conducted a systematic review and meta-analysis across three scientific databases (Global Index Medicus, Web of Science, and PubMed) to analyze relationships between chewing tobacco and stroke, ischemic heart disease, and five types of cancer of the neck and head.

    The search included publications regardless of their language and papers published from 1970 onwards. They used meta-regressions and Bayesian methods to estimate a measure of pooled relative risk and then obtained an effect size for each health outcome. Of the literature obtained from the search, 4,480 were excluded, and 111 were included in the analysis.

    Findings

    Three studies conducted in Bangladesh and India included data on chewing tobacco and stroke; the meta-analysis suggested that conservatively, using smoking tobacco products increased the risk of stroke by 16%. This association is classified as a ‘weak’ relationship. However, these findings were robust to various validations; no publication or covariate bias was detected.

    Eight studies examined associations between smokeless tobacco and ischemic heart disease, most of which were conducted in Bangladesh, India, and the United States. The meta-analysis found no evidence that chewing tobacco significantly changed ischemic heart disease risk; again, researchers found no evidence of publication bias or covariate bias.

    For esophageal cancer, 22 studies were identified; analysis suggested that using chewing tobacco significantly increased the risk of cancer by 2% conservatively. However, a meta-analytic approach yielded a higher estimate of a 2.14-fold increase in esophageal cancer risk. Smoking status, sex, and age were adjusted for in the final analysis, and no publication bias was detected.

    A total of 70 studies examined associations between smokeless tobacco products and cancers of the lip and oral cavity. The analysis incorporated numerous sources of uncertainty and found a relative risk factor of 3.64, and the association was characterized as weak; the risk of developing these forms of cancer increased when the sample was restricted to studies conducted in Asian countries.

    The effect size for laryngeal cancer was estimated from 24 studies. Researchers found that evidence regarding this outcome was weak after accounting for sources of uncertainty, while the relative risk factor was 2.66. However, for a single study, the relationship between smokeless tobacco and laryngeal cancer was significantly higher.

    17 studies were included for nasopharyngeal cancer, and weak evidence of a relationship with a relative risk measure of 2.50 was seen. Age and sex were included in the model after covariate selection, and no evidence of publication bias was found.

    The outcome included in the meta-analysis was other cancers of the pharynx; data for this model was obtained from 31 studies. The relative risk factor was 2.33, and the association was characterized as weak. However, using a subset of the data, a higher risk measure of 4.38 was found, showing a stronger association.

    Conclusions

    The study had various strengths, including reducing the impact of geographical variation. Of the seven health outcomes included, six showed at least weak evidence of increased risk faced by smokeless tobacco users; the only outcome for which no evidence was found was ischemic heart disease. The highest risks were of stroke and esophageal cancer, with a conservative estimate suggesting an increase in incidence of 2-16%.

    An important conclusion was that while chewing tobacco is considered a carcinogen, the literature predominantly examined its relationship with lip, oral cavity, and esophageal cancer, highlighting the need for more high-quality studies on associations with other cancers of the head and neck. Specifically, nasopharyngeal and laryngeal cancer should also merit careful observation in the future, as should stroke.

    Limitations of the study included the variety of smokeless tobacco products, exposure definitions, and geographical settings. The approach followed in this study was also not able to estimate dose-response relationships. However, these findings can be used by public health workers to better counsel clients on harms associated with smoking tobacco products and advocate for more effective public health policies, while they may also be of interest to community awareness campaigns.

    Journal reference:

    • Health effects associated with chewing tobacco: A Burden of Proof study. Gil, G.F., Anderson, J.A., Aravkin, A., Bhangdia, K., Carr, S., Dai, X., Flor, L.S., Hay, S.I., Matthew, M.J., McLaughlin, S.A., Mullany, E.C., Murray, C.J.L., O’Connell, E.M., Okereke, C., Sorensen, R.J.D., Whisnant, J., Zheng, P., Gakidou, E. Nature Communications (2024). 10.1038/s41467-024-45074-9, https://www.nature.com/articles/s41467-024-45074-9

    [ad_2]

    Source link

  • Single-port robot introduced in the Mountain West for head and neck surgical cancer patients

    Single-port robot introduced in the Mountain West for head and neck surgical cancer patients

    [ad_1]

    Huntsman Cancer Institute at the University of Utah (the U) proudly introduces the first and only single-port robot in the Mountain West for head and neck surgical oncology patients. This state-of-the-art technology is a groundbreaking step in the field of oncological surgery, allowing for greater precision and less invasive procedures. Under the visionary leadership of dedicated healthcare professionals, the institute is committed to revolutionizing treatments for cancer patients.

    I am delighted that Huntsman Cancer Institute can now offer cancer patients in the Mountain West access to this innovative and life-changing technology. While our surgeons have been conducting robotic cancer surgery for over a decade, the single-port robot represents a significant advancement that can substantially improve recovery time and minimize side-effects in select patients.”


    Sachin Apte, MD, MS, MBA, chief clinical officer at Huntsman Cancer Institute, physician-in-chief of the cancer hospital, and professor of obstetrics and gynecology at the U

    The first person to have this procedure in the Mountain West will be 34-year-old Salt Lake City resident Reyes Salazar. The new robot will remove a non-cancerous cyst from the back of his throat. Doctors discovered a cyst near his airway when he was eight and despite successful laser removal, the cyst has reemerged. “If it were to roll over and block my air passage, I could suffocate in my sleep without even knowing,” remarks Salazar. “So, I prefer not to really take it lightly.”

    Hilary McCrary, MD, MPH, head and neck surgical oncologist and microvascular reconstruction surgeon at Huntsman Cancer Institute and assistant professor of otolaryngology at the U, will be conducting the surgery. She first learned robotic surgery during residency, and received comprehensive training in the full spectrum of head and neck cancer care during her fellowship at Ohio State University. 

    “After all these years, my body has been through enough trauma from past operations,” Salazar says. “I can finally give my body the peace of mind and rest that it needs.” Despite his nerves about the upcoming procedure, Salazar remains overwhelmingly optimistic and holds high hopes for success, not only for himself but for others in similar situations.

    Before the Food and Drug Administration (FDA) granted approval for the utilization of robots in head and neck surgeries, procedures that allowed access to the back of the throat required surgeons to split the mandible, or lower jawbone, to access areas that were otherwise inaccessible. McCrary envisions a bright, promising future for robotic surgery and believes that this technological leap forward will expand possibilities and increase the number of patients eligible for treatment.

    The single-port robot is equipped with novel instrumentation and technology tailored to perform effectively within a narrow field. It incorporates a state-of-the-art camera with the capability to change shape, providing increased visibility around corners, which proves valuable when dealing with tumors in the base of the tongue or supraglottic region. This advanced method is becoming the national standard of care among head and neck practitioners, offering patients the potential for faster recovery, reduced scarring, and improved outcomes.

    Huntsman Cancer Institute first opened its robotic surgery program in 2011 and remains one of the most advanced and comprehensive in the U.S. today. With 15 surgeons performing in a variety of specialized cancer procedures, they have completed over 5,000 robotic operations to date.

    While head and neck cancers may develop for a variety reasons, the American Cancer Society (ACS) states that the human papillomavirus (HPV), makes up for most cancers found in the back of the throat and can be linked to other cancer types. Individuals are strongly encouraged to consider receiving the HPV vaccine as a preventative measure. 

    [ad_2]

    Source link